TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22906371

Group type: EXPERIMENTAL
Intervention: Bone-anchored maxillary expander (BAME) treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study: 21046863

Group type: EXPERIMENTAL
Intervention: Ten minute medication review by a general practitioner
Number of subjects: 50
Study: 17373899

Group type: EXPERIMENTAL
Intervention: Human papillomavirus vaccine
Number of subjects: 0
Study: 16485865

Group type: EXPERIMENTAL
Intervention: Health advocacy, counseling, and activation program (16 lectures, 8 group discussions, 6 exercise sessions, 3 social activities)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Health advocacy, counseling, and activation program
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 227
Study: 11903235

Group type: EXPERIMENTAL
Intervention: Terbinafine for 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbinafine for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole for 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole for 3 months
Number of subjects: 0
Study: 10470696

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin, methotrexate, and vinblastine, with folinic acid rescue)
Number of subjects: 976

Group type: COMPARATOR
Intervention: No chemotherapy (control)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 976
Study: 7782463

Group type: EXPERIMENTAL
Intervention: Exner administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: first Exner administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rapaport administration
Number of subjects: 20
Study: 2184796

Group type: EXPERIMENTAL
Intervention: High-dose levothyroxine sodium added to a stable regimen of medications
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo substitution (single- or double-blind)
Number of subjects: 11
Study: 424377

Group type: EXPERIMENTAL
Intervention: Stepped Care
Number of subjects: 11237

Group type: COMPARATOR
Intervention: Referred Care
Number of subjects: 11237
Study: 31615585

Group type: EXPERIMENTAL
Intervention: Prucalopride (1 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31012498

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (laparoscopic)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Open distal pancreatectomy
Number of subjects: 104
Study: 29149915

Group type: EXPERIMENTAL
Intervention: Safewards intervention
Number of subjects: 565
Study: 25410983

Group type: EXPERIMENTAL
Intervention: ALA-mediated PDT (20% ALA solution, 1.5 h incubation, 630 nm red light, 80 J/cm(2))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Red light alone
Number of subjects: 26
Study: 24330570

Group type: EXPERIMENTAL
Intervention: Soccer training (12 weeks, 2-3 times/week for 45-60 min)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Soccer training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study: 22032998

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no kinesio taping)
Number of subjects: 31
Study: 19858394

Group type: EXPERIMENTAL
Intervention: VMP (bortezomib 1.3 mg/m², melphalan 9 mg/m², prednisone 60 mg/m²)
Number of subjects: 227

Group type: COMPARATOR
Intervention: MP (melphalan and prednisone)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: VMP
Number of subjects: 227

Group type: COMPARATOR
Intervention: MP
Number of subjects: 227
Study: 17118098

Group type: EXPERIMENTAL
Intervention: Peripheral electrical nerve stimulation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham stimulation (placebo)
Number of subjects: 62
Study: 15659884

Group type: EXPERIMENTAL
Intervention: Multidisciplinary adherence intervention
Number of subjects: 68
Study: 11712719

Group type: EXPERIMENTAL
Intervention: Single-session music therapy interventions
Number of subjects: 80
Study: 9024176

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Montelukast 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Montelukast 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Montelukast 250 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Montelukast 40 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Montelukast 200 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8127465

Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS) with velocities ranging from -100 to +100 degree/sec
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS) with upward velocities
Number of subjects: 10
Study: 3722374

Group type: EXPERIMENTAL
Intervention: Air at body conditions during exercise
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Increasing heat content of air during recovery
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Controlling ventilation during recovery from hyperventilation of frigid air
Number of subjects: 17

Group type: COMPARATOR
Intervention: Frigid air inhalation during exercise
Number of subjects: 17
Study: 31923161

Group type: EXPERIMENTAL
Intervention: Progrip (PG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Fibrin Sealant (FS)
Number of subjects: 150
Study: 28991119

Group type: EXPERIMENTAL
Intervention: High operating table at xiphoid process (group X)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High operating table at nipple level (group N)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High operating tables at umbilicus (group U) and lowest rib margin (group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High operating tables (groups X and N)
Number of subjects: 60
Study: 26620100

Group type: EXPERIMENTAL
Intervention: Intentionally high restorations (0.5mm supraocclusion)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group with restorations without intentional increase of occlusal vertical dimension
Number of subjects: 17
Study: 24402888

Group type: EXPERIMENTAL
Intervention: Stapler transection
Number of subjects: 130

Group type: COMPARATOR
Intervention: Clamp-crushing
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study: 22566113

Group type: EXPERIMENTAL
Intervention: Oral probiotics
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 221
Study: 20517212

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrostimulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 18442104

Group type: EXPERIMENTAL
Intervention: Thalamic stimulation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Thalamotomy
Number of subjects: 68
Study: 15918060

Group type: EXPERIMENTAL
Intervention: Open‐circuit acetylene uptake (OpCirc)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Single‐breath acetylene uptake (SB)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CO2 rebreathing (CO2RB)
Number of subjects: 13
Study: 12483234

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) 0.2%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propylene glycol alginate (PGA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 24% Ethylenediaminetetra-acetate (EDTA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (NaCl)
Number of subjects: 14
Study: 10529124

Group type: EXPERIMENTAL
Intervention: Cyclosporine A 2.5 mg/kg/day
Number of subjects: 244

Group type: COMPARATOR
Intervention: Cyclosporine A 1.5 mg/kg/day
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 7720447

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 16
Study: 2183346

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Fuji III)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diluted composite (Control)
Number of subjects: 20
Study: 6753707

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diphenoxylate
Number of subjects: 29
Study: 6388523

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 61
Study: 29493047

Group type: EXPERIMENTAL
Intervention: Epirubicin treatment group
Number of subjects: 980
Study: 27759816

Group type: EXPERIMENTAL
Intervention: FP Group (fentanyl 1mcg/kg and propofol 1.5mg/kg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: MRPB Group (midazolam 0.075mg/kg and remifentanil 0.25mcg/kg/min with paracervical block with 3mL of 2% lidocaine)
Number of subjects: 61
Study: 23639070

Group type: EXPERIMENTAL
Intervention: Working memory training (adaptive n-back training, 12 sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Working memory training (adaptive n-back training)
Number of subjects: 60
Study: 22499839

Group type: EXPERIMENTAL
Intervention: Stent placement for extracranial ICA stenosis
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal CirT (control group)
Number of subjects: 59
Study: 20525323

Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire (SAQ) scales: Exertional Capacity Scale (ECS), Disease Perception Scale (DPS), Anginal Frequency Scale (AFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic variables (age, gender, disease stage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treadmill exercise time (ETT) and Canadian Cardiovascular Society (CCS) angina severity class
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predicted EQ‐5D index values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mapping of EQ‐5D index
Number of subjects: 0
Study: 18827247

Group type: EXPERIMENTAL
Intervention: One cage (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Two cages (group 2)
Number of subjects: 100
Study: 15886860

Group type: EXPERIMENTAL
Intervention: Coca Cola (2.5 l per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Semi-skimmed milk (2.5 l per day)
Number of subjects: 11
Study: 11803087

Group type: EXPERIMENTAL
Intervention: Cell culture-derived vaccine
Number of subjects: 940

Group type: COMPARATOR
Intervention: Egg-derived vaccine
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 940
Study: 10404100

Group type: EXPERIMENTAL
Intervention: PSA >/= 3 ng/ml as a direct biopsy indicator
Number of subjects: 0

Group type: COMPARATOR
Intervention: PSA < 4 ng/ml with DRE and TRUS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic-regression model predicting cancers for PSA < 4 ng/ml
Number of subjects: 0
Study: 7587256

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 0.037 g/kg bolus followed by 0.025 g/kg/hr infusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Amiodarone 5 mg/kg bolus and 10 mg/kg/24-hr infusion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 42
Study: 2262840

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 100

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 100
Study: 6249047

Group type: EXPERIMENTAL
Intervention: Supercol (experiment B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mannucol (experiment C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 g glucose (experiment A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo substance (experiment D)
Number of subjects: 40
Study: 30358116

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg + Dutasteride 0.5 mg + Imidafenacin 0.2 mg (TDI)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Tamsulosin + Dutasteride (TD)
Number of subjects: 163
Study: 29352704

Group type: EXPERIMENTAL
Intervention: High-dose E1224 (4000 mg over 8 weeks)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Low-dose E1224 (2000 mg over 8 weeks)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Short-dose E1224 (2400 mg over 4 weeks + 4 weeks placebo)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Benznidazole (5 mg/kg per day for 60 days)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo (E1224-matched tablets for 8 weeks)
Number of subjects: 231
Study: 26386865

Group type: EXPERIMENTAL
Intervention: Kinect training three times a week for 3 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal activities
Number of subjects: 13
Study: 24411476

Group type: EXPERIMENTAL
Intervention: Sheepskin mattress (SSM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sheepskin mattress combined with control mattress (SSM+CM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control mattress (CM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard hospital mattress (SHM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Alternative mattress combined with control mattress (AM+CM)
Number of subjects: 18
Study: 22301195

Group type: EXPERIMENTAL
Intervention: Citalopram (target dose of 30 mg/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 200
Study: 19204566

Group type: EXPERIMENTAL
Intervention: Combined sprint and resistance training (SRT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sprint training only (ST)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Resistance training only (RT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SRT and ST groups
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SRT group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All training groups
Number of subjects: 25
Study: 17994478

Group type: EXPERIMENTAL
Intervention: Modified Therapeutic Community (MTC)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 139
Study: 16389980

Group type: EXPERIMENTAL
Intervention: Dual-exposure DE subtraction chest radiography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chest radiography alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chest radiography with DE subtraction images
Number of subjects: 100
Study: 11733877

Group type: EXPERIMENTAL
Intervention: Symmetrical body-weight distribution training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional stroke rehabilitation program
Number of subjects: 54
Study: 9015133

Group type: EXPERIMENTAL
Intervention: Single bolus dose of 5 mg Cr(VI)/L in drinking water (0.5 L swallowed in 2 min)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Single bolus dose of 10 mg Cr(VI)/L in drinking water (0.5 L swallowed in 2 min)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Repeated exposure to 5 mg Cr(VI)/L in drinking water (1 L/d for 3 days, 3 doses of 0.33 L each day at 6-h intervals)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Repeated exposure to 10 mg Cr(VI)/L in drinking water (1 L/d for 3 days, 3 doses of 0.33 L each day at 6-h intervals)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Overall ingestion of Cr(VI) at 5 and 10 mg Cr(VI)/L
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ingestion of Cr(VI) on an empty stomach
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chemical environment in the gastrointestinal tract and blood
Number of subjects: 5
Study: 8314361

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cimetidine, Ranitidine, Famotidine (combined effect)
Number of subjects: 6
Study: 3662156

Group type: EXPERIMENTAL
Intervention: Reading a three-page review (n = 33)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Viewing a 15-minute videotape (n = 34)
Number of subjects: 67
Study: 31136622

Group type: EXPERIMENTAL
Intervention: Playing to predictable beats
Number of subjects: 2

Group type: COMPARATOR
Intervention: Playing to unpredictable beats
Number of subjects: 2

Group type: COMPARATOR
Intervention: Rhythmic patterns that were similar, predictable, or independent
Number of subjects: 2
Study: 28507362

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 28
Study: 26027814

Group type: EXPERIMENTAL
Intervention: Daily conversational interactions using remote video telecommunications software
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal cognitive function (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression model including average proportion of word counts spoken by subjects
Number of subjects: 0
Study: 23688821

Group type: EXPERIMENTAL
Intervention: HF meal rich in MUFAs (42% of total energy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HF meal rich in SFAs (45% of total energy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HF meal rich in PUFAs (42% of total energy)
Number of subjects: 15
Study: 21142584

Group type: EXPERIMENTAL
Intervention: Prefabricated occlusal appliance (R)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Stabilization appliance (S)
Number of subjects: 66
Study: 19262219

Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 71

Group type: COMPARATOR
Intervention: PEEP 0 cmH2O (Control Group)
Number of subjects: 71
Study: 16740812

Group type: EXPERIMENTAL
Intervention: Timely patient feedback in the form of a letter providing recent patient-specific symptoms, medication, and health service use combined with guideline-based recommendations for changes in therapy.
Number of subjects: 937

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 937
Study: 15615259

Group type: EXPERIMENTAL
Intervention: LSG9 (VEPA-B/FEPP-AB/M-FEPA, treated 3 times every 10 weeks for 28 weeks total)
Number of subjects: 447

Group type: COMPARATOR
Intervention: mLSG4 (VEPA-B/FEPP-B/M-FEPA, treated 4 times every 14 weeks for 54 weeks total)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: LSG9
Number of subjects: 447

Group type: COMPARATOR
Intervention: mLSG4
Number of subjects: 447
Study: 11731187

Group type: EXPERIMENTAL
Intervention: 1 mg E(2)V + 2.5 mg MPA
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: 1 mg E(2)V + 5 mg MPA
Number of subjects: 440

Group type: COMPARATOR
Intervention: 2 mg E(2) + 1 mg NETA
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: E(2)V/MPA (increased to 2 mg after 6 months)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: All dose combinations
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 440

Group type: COMPARATOR
Intervention: E(2)/NETA
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: E(2)V/MPA
Number of subjects: 440
Study: 8607227

Group type: EXPERIMENTAL
Intervention: Terazosin (1 mg daily for 3 days, then 2 mg daily for 25 days, titrated to 5 or 10 mg if needed)
Number of subjects: 2084

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 2084
Study: 1544220

Group type: EXPERIMENTAL
Intervention: Interferon‐alpha 2b (IFN‐alpha 2b) treatment, 3 x 10(6) U three times weekly for 36 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Interferon‐alpha 2b (IFN‐alpha 2b) treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not treated with IFN‐alpha 2b)
Number of subjects: 33
Study: 3907893

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Third-line therapy (general)
Number of subjects: 10
Study: 30277500

Group type: EXPERIMENTAL
Intervention: Semiannual influenza vaccination (IIV3)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (tetanus-diphtheria-pertussis vaccination)
Number of subjects: 200
Study: 30468238

Group type: EXPERIMENTAL
Intervention: Resistant starch (16 g of resistant starch Hi‐Maize® 260)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (manioc flour)
Number of subjects: 31
Study: 26724745

Group type: EXPERIMENTAL
Intervention: Vitamin D (200,000 IU at first, followed by 25,000 IU every 2 weeks)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 24795475

Group type: EXPERIMENTAL
Intervention: Single vaccine dose of unadjuvanted split‐virus H1N1 A/California/07/2009 influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of unadjuvanted split‐virus H1N1 A/California/07/2009 influenza vaccine
Number of subjects: 0
Study: 22613104

Group type: EXPERIMENTAL
Intervention: Compound prescription (radix astragali + codonopsis pilosula + tortoise plastron)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Radix astragali
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 57
Study: 20830787

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b with or without lamivudine for 52 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Combination therapy (PEG‐IFN with lamivudine)
Number of subjects: 221

Group type: COMPARATOR
Intervention: No decline at week 12
Number of subjects: 221
Study: 18855259

Group type: EXPERIMENTAL
Intervention: Amiloride 2.5-5 mg/day
Number of subjects: 82

Group type: COMPARATOR
Intervention: Enalapril 10-20 mg/day
Number of subjects: 82
Study: 15700156

Group type: EXPERIMENTAL
Intervention: Medical personnel's evaluation of therapy goals
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Medical personnel's evaluation of psychological distress and social improvements
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Medical personnel's evaluation of therapeutic expenditure
Number of subjects: 133
Study: 12441218

Group type: EXPERIMENTAL
Intervention: Lipoprotein (a) serum levels (Lp(a))
Number of subjects: 118
Study: 10355867

Group type: EXPERIMENTAL
Intervention: L-arginine intake (3.8 g/d) during diet B
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nitrate/nitrite-free diet with no L-arginine intake during diet A
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both diets (A and B)
Number of subjects: 8